AR031924A1 - Anticuerpos anti-cd28 silenciados y el uso de estos - Google Patents
Anticuerpos anti-cd28 silenciados y el uso de estosInfo
- Publication number
- AR031924A1 AR031924A1 ARP010105828A ARP010105828A AR031924A1 AR 031924 A1 AR031924 A1 AR 031924A1 AR P010105828 A ARP010105828 A AR P010105828A AR P010105828 A ARP010105828 A AR P010105828A AR 031924 A1 AR031924 A1 AR 031924A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- silenced
- methods
- tissues
- defective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25515500P | 2000-12-14 | 2000-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031924A1 true AR031924A1 (es) | 2003-10-08 |
Family
ID=22967074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105828A AR031924A1 (es) | 2000-12-14 | 2001-12-14 | Anticuerpos anti-cd28 silenciados y el uso de estos |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1341553A4 (cs) |
| JP (1) | JP2004515243A (cs) |
| KR (1) | KR20040020866A (cs) |
| CN (1) | CN1272345C (cs) |
| AR (1) | AR031924A1 (cs) |
| AU (2) | AU2002226086C1 (cs) |
| BR (1) | BR0116686A (cs) |
| CA (1) | CA2432736A1 (cs) |
| CZ (1) | CZ20031909A3 (cs) |
| HU (1) | HUP0400697A3 (cs) |
| IL (1) | IL156262A0 (cs) |
| MX (1) | MXPA03005327A (cs) |
| NO (1) | NO20032542L (cs) |
| NZ (1) | NZ526569A (cs) |
| PL (1) | PL363239A1 (cs) |
| RU (1) | RU2261723C2 (cs) |
| WO (1) | WO2002047721A1 (cs) |
| ZA (1) | ZA200305384B (cs) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
| SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
| FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
| HUE039677T2 (hu) * | 2010-02-18 | 2019-01-28 | Ose Immunotherapeutics | Humanizált anti-CD28-ellenanyagok |
| MX2019004580A (es) | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CA3130348A1 (en) * | 2019-03-14 | 2020-09-17 | Motti HAKIM | A method for immunosuppression |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580756A (en) * | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
-
2001
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/ko not_active Application Discontinuation
- 2001-12-14 IL IL15626201A patent/IL156262A0/xx unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/es unknown
- 2001-12-14 CN CNB018226361A patent/CN1272345C/zh not_active Expired - Fee Related
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Application Discontinuation
- 2001-12-14 AR ARP010105828A patent/AR031924A1/es unknown
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/cs unknown
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/hu unknown
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2608602A patent/AU2608602A/xx active Pending
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/ru not_active IP Right Cessation
- 2001-12-14 PL PL01363239A patent/PL363239A1/xx not_active Application Discontinuation
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/ja not_active Withdrawn
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/no not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1341553A1 (en) | 2003-09-10 |
| PL363239A1 (en) | 2004-11-15 |
| HUP0400697A2 (hu) | 2004-06-28 |
| CN1272345C (zh) | 2006-08-30 |
| CA2432736A1 (en) | 2002-06-20 |
| MXPA03005327A (es) | 2004-12-03 |
| RU2003121231A (ru) | 2005-02-10 |
| JP2004515243A (ja) | 2004-05-27 |
| KR20040020866A (ko) | 2004-03-09 |
| CZ20031909A3 (cs) | 2003-11-12 |
| RU2261723C2 (ru) | 2005-10-10 |
| EP1341553A4 (en) | 2004-07-28 |
| CN1489473A (zh) | 2004-04-14 |
| NZ526569A (en) | 2005-07-29 |
| NO20032542L (no) | 2003-08-07 |
| AU2608602A (en) | 2002-06-24 |
| AU2002226086C1 (en) | 2006-03-09 |
| WO2002047721A1 (en) | 2002-06-20 |
| NO20032542D0 (no) | 2003-06-05 |
| IL156262A0 (en) | 2004-01-04 |
| AU2002226086B2 (en) | 2005-08-25 |
| BR0116686A (pt) | 2003-12-30 |
| ZA200305384B (en) | 2004-10-11 |
| HUP0400697A3 (en) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031924A1 (es) | Anticuerpos anti-cd28 silenciados y el uso de estos | |
| MX2009003588A (es) | Composiciones de colageno placentario (telopeptido), natural. | |
| ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
| UY24256A1 (es) | Anticuerpos monoclonales de mono especificos para anticuerpos humanos b 7.1 y/o b7.2, formas primatizadas de los mis- mos, composiciones farmaceuticas que los contienen y uso de los mismos como inmunosupresores | |
| BR0114630A (pt) | Secretagogos de hormÈnio do crescimento | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| ATE529125T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung | |
| GT200300031A (es) | Indazoles substitutos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| CY1109413T1 (el) | Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα | |
| BR0214029A (pt) | Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas | |
| BR0210593A (pt) | polinucleotìdeos de defensina e métodos de uso | |
| AR023463A1 (es) | Uso de compuestos de azetidinona | |
| ATE481092T1 (de) | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen | |
| BRPI0607883A2 (pt) | método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular | |
| TR200401638T2 (tr) | Bir reseptöre bağlanan peptidler ve bileşikler. | |
| ECSP045146A (es) | Moléculas pequeñas para el tratamiento del crecimiento celular anormal | |
| BR0210599A (pt) | Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| ECSP034924A (es) | Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno | |
| BRPI0607504A2 (pt) | população de suìnos que possui baixos nìveis de retrovìrus endógenos suìnos e usos dos mesmos | |
| BR0307629A (pt) | Métodos e composições para tratar condições hiperproliferativas | |
| GT200300046A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| HK1205531A1 (en) | Mesenchymal stem cells and uses therefor | |
| BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
| DE69721021D1 (de) | Blasenmukosa mit zellen für die rekonstruktion von geweben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |